newsfilter
← Latest News
GlobeNewswire·

Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025

NORCROSS, Ga., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today